{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:38:54Z","timestamp":1782275934133,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To assess outcomes of patients with carcinoma of the anal canal (CAC) treated with intensity-modulated radiation therapy (IMRT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method and materials<\/jats:title>\n            <jats:p>From August 2007 to January 2011, seventy-two patients suffering from CAC were treated with IMRT. Concurrent chemotherapy was added in case of locally advanced tumors. Radiation course consisted in delivering an initial plan to the PTV1 defined as the primary tumor and the risk area including pelvic and inguinal nodes. Forty-five Gy in daily 1.8 Gy-daily fractions were delivered five days a week. A second plan of 14.4-20 Gy to the primary tumor (PTV2) was administered in 1.8-2 Gy-daily fractions, 5 days a week. We present here the results of dosimetry, toxicities, and clinical outcome of the first 39 patients with a median follow-up of 24 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-one women and eight men were included in the present analysis. Tumors were classified as stages I, II, III and IV in 2, 7, 27 and 2 patients, respectively. Median age was 59 years (range, 38-85). Radiotherapy alone (RT) or combined with chemotherapy (RCT) were delivered in 6 (15%) and 33 (85%) patients, respectively.<\/jats:p>\n            <jats:p>Six patients (15%) required a treatment break \u2265 3 days, and median time for treatment break was 8 days (range, 3-14 days). Acute grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities were seen in 10 and 5% of patients, respectively. Grade 4 toxicity was only hematologic and occurred in 12% patients receiving RCT. With a median follow-up of 24 months, no patient experienced any late grade 4 toxicity. The 2-year overall survival rate was 89%, the 2-year local relapse free survival was 77% and the 2-year colostomy-free survival rate was 85%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IMRT is well tolerated with acceptable treatment interruption allowing dose escalation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1748-717x-7-45","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T18:35:55Z","timestamp":1332527755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center"],"prefix":"10.1186","volume":"7","author":[{"given":"Sabine","family":"Vieillot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Fenoglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Llacer","family":"Moscardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Aill\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,23]]},"reference":[{"key":"550_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<805::AID-CNCR20>3.0.CO;2-W","volume":"80","author":"RJ Myerson","year":"1997","unstructured":"Myerson RJ, Karnell LH, Menck HR: The National Cancer Data Base report on carcinoma of the anus. Cancer 1997, 80: 805-815. 10.1002\/(SICI)1097-0142(19970815)80:4<805::AID-CNCR20>3.0.CO;2-W","journal-title":"Cancer"},{"key":"550_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/BF02553933","volume":"27","author":"ND Nigro","year":"1984","unstructured":"Nigro ND: An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum 1984, 27: 763-766. 10.1007\/BF02553933","journal-title":"Dis Colon Rectum"},{"key":"550_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/1097-0142(19830515)51:10<1830::AID-CNCR2820511013>3.0.CO;2-Z","volume":"51","author":"J Papillon","year":"1983","unstructured":"Papillon J, Mayer M, Montbarbon JF, Gerard JP, Chassard JL, Bailly C: A new approach to the management of epidermoid carcinoma of the anal canal. Cancer 1983, 51: 1830-1837. 10.1002\/1097-0142(19830515)51:10<1830::AID-CNCR2820511013>3.0.CO;2-Z","journal-title":"Cancer"},{"key":"550_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","year":"1996","unstructured":"UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research: Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996, 348: 1049-1054.","journal-title":"Lancet"},{"key":"550_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15: 2040-2049.","journal-title":"J Clin Oncol"},{"key":"550_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2329::AID-CNCR6>3.0.CO;2-G","volume":"79","author":"AS Allal","year":"1997","unstructured":"Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM: The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 1997, 79: 2329-2335. 10.1002\/(SICI)1097-0142(19970615)79:12<2329::AID-CNCR6>3.0.CO;2-G","journal-title":"Cancer"},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","volume":"50","author":"DC Weber","year":"2001","unstructured":"Weber DC, Kurtz JM, Allal AS: The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001, 50: 675-680. 10.1016\/S0360-3016(01)01510-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijrobp.2005.05.052","volume":"63","author":"YJ Chen","year":"2005","unstructured":"Chen YJ, Liu A, Tsai PT, Vora NL, Pezner RD, Schultheiss TE, Wong JY: Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal\/femoral nodes. Int J Radiat Oncol Biol Phys 2005, 63: 274-281. 10.1016\/j.ijrobp.2005.05.052","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3816\/CCC.2007.n.041","volume":"6","author":"A Lin","year":"2007","unstructured":"Lin A, Ben-Josef E: Intensity-modulated radiation therapy for the treatment of anal cancer. Clin Colorectal Cancer 2007, 6: 716-719. 10.3816\/CCC.2007.n.041","journal-title":"Clin Colorectal Cancer"},{"key":"550_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1748-717X-2-41","volume":"2","author":"C Menkarios","year":"2007","unstructured":"Menkarios C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2: 41. 10.1186\/1748-717X-2-41","journal-title":"Radiat Oncol"},{"key":"550_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","volume":"63","author":"MT Milano","year":"2005","unstructured":"Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63: 354-361. 10.1016\/j.ijrobp.2005.02.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.ijrobp.2009.09.046","volume":"78","author":"JM Pepek","year":"2010","unstructured":"Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG: Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010, 78: 1413-1419. 10.1016\/j.ijrobp.2009.09.046","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR13","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","volume":"25","author":"JK Salama","year":"2007","unstructured":"Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25: 4581-4586. 10.1200\/JCO.2007.12.0170","journal-title":"J Clin Oncol"},{"key":"550_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S0360-3016(02)03801-4","volume":"54","author":"CJ Brixey","year":"2002","unstructured":"Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ: Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 54: 1388-1396. 10.1016\/S0360-3016(02)03801-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0360-3016(03)00521-2","volume":"57","author":"AE Lujan","year":"2003","unstructured":"Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC: Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57: 516-521. 10.1016\/S0360-3016(03)00521-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","volume":"66","author":"LK Mell","year":"2006","unstructured":"Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ: Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66: 1356-1365. 10.1016\/j.ijrobp.2006.03.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","volume":"70","author":"LK Mell","year":"2008","unstructured":"Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ: Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70: 1431-1437. 10.1016\/j.ijrobp.2007.08.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"Cancer staging manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, Blach CM, Fleming ID: Cancer staging manual. 6th edition. Edited by: AJCC. New York: Springer; 2002.","edition":"6"},{"key":"550_CR19","volume-title":"Report no. 50. Prescribing, recording, and reporting photon beam therapy","author":"International Commission on Radiation Units and Measurements","year":"1993","unstructured":"International Commission on Radiation Units and Measurements: Report no. 50. Prescribing, recording, and reporting photon beam therapy. Washington: DC: ICRU; 1993."},{"key":"550_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.ijrobp.2005.05.062","volume":"63","author":"A Taylor","year":"2005","unstructured":"Taylor A, Rockall AG, Reznek RH, Powell ME: Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63: 1604-1612. 10.1016\/j.ijrobp.2005.05.062","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.radonc.2009.07.006","volume":"93","author":"K Devisetty","year":"2009","unstructured":"Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC, Aydogan B, Chmura SJ: A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol 2009, 93: 298-301. 10.1016\/j.radonc.2009.07.006","journal-title":"Radiother Oncol"},{"key":"550_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299: 1914-1921. 10.1001\/jama.299.16.1914","journal-title":"JAMA"},{"key":"550_CR23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ijrobp.2008.04.046","volume":"71","author":"LK Mell","year":"2008","unstructured":"Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B: Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008, 71: 1504-1510. 10.1016\/j.ijrobp.2008.04.046","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","volume":"31","author":"P Mauch","year":"1995","unstructured":"Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, Deeg HJ: Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995, 31: 1319-1339. 10.1016\/0360-3016(94)00430-S","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"550_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1748-717X-5-92","volume":"5","author":"S Vieillot","year":"2010","unstructured":"Vieillot S, Azria D, Lemanski C, Moscardo CL, Gourgou S, Dubois JB, Ailleres N, Fenoglietto P: Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol 2010, 5: 92. 10.1186\/1748-717X-5-92","journal-title":"Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-7-45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:51:32Z","timestamp":1630522292000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-7-45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-7-45","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,23]]},"assertion":[{"value":"4 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"45"}}